Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. More Details
Mediocre balance sheet with weak fundamentals.
Share Price & News
How has Eloxx Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ELOX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: ELOX's weekly volatility (12%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: ELOX matched the US Pharmaceuticals industry which returned 9.6% over the past year.
Return vs Market: ELOX underperformed the US Market which returned 55% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Eloxx Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StWhat Kind Of Investors Own Most Of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)?
5 months ago | Simply Wall StHow Many Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Shares Do Institutions Own?
9 months ago | Simply Wall StCould The Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Ownership Structure Tell Us Something Useful?
Is Eloxx Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ELOX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ELOX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ELOX is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: ELOX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ELOX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ELOX is overvalued based on its PB Ratio (9.3x) compared to the US Pharmaceuticals industry average (3.8x).
How is Eloxx Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ELOX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ELOX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ELOX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if ELOX's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if ELOX's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ELOX's Return on Equity is forecast to be high in 3 years time
How has Eloxx Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ELOX is currently unprofitable.
Growing Profit Margin: ELOX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ELOX is unprofitable, and losses have increased over the past 5 years at a rate of 23.5% per year.
Accelerating Growth: Unable to compare ELOX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ELOX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.8%).
Return on Equity
High ROE: ELOX has a negative Return on Equity (-338%), as it is currently unprofitable.
How is Eloxx Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: ELOX's short term assets ($25.9M) exceed its short term liabilities ($9.8M).
Long Term Liabilities: ELOX's short term assets ($25.9M) exceed its long term liabilities ($6.4M).
Debt to Equity History and Analysis
Debt Level: ELOX's debt to equity ratio (113.5%) is considered high.
Reducing Debt: Insufficient data to determine if ELOX's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ELOX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ELOX has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 27% each year.
What is Eloxx Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ELOX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ELOX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ELOX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ELOX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ELOX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sumit Aggarwal (47 yo)
Mr. Sumit Aggarwal, MBA serves as a Director at Eloxx Pharmaceuticals, Inc. since April 01, 2021. He is the President and Chief Executive Officer of Eloxx Pharmaceuticals, Inc. since April 01, 2021. He ser...
Experienced Management: ELOX's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Experienced Board: ELOX's board of directors are considered experienced (3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.2%.
Eloxx Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Eloxx Pharmaceuticals, Inc.
- Ticker: ELOX
- Exchange: NasdaqGM
- Founded: 2013
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$113.792m
- Shares outstanding: 47.81m
- Website: https://www.eloxxpharma.com
Number of Employees
- Eloxx Pharmaceuticals, Inc.
- 950 Winter Street
- United States
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon dise...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/22 19:06|
|End of Day Share Price||2021/04/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.